RecruitingPhase 3NCT06765161
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
Sponsor
Clinique Neuro-Outaouais
Enrollment
30 participants
Start Date
Feb 6, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called efgartigimod administration for people with myasthaenia gravis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGefgartigimod administration
efgartigimod infusion
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06765161
Related Trials
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
NCT0679924734 locations
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
NCT074031881 location
Myasthenia Gravis Foundation of America Global MG Patient Registry
NCT066177411 location